Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SHEEBA KOSHY THOMAS and ELIZABETH SHPALL.
Connection Strength

1.198
  1. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol. 2024 Nov 28.
    View in: PubMed
    Score: 0.062
  2. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 10 31; 14(1):189.
    View in: PubMed
    Score: 0.062
  3. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplant Cell Ther. 2024 Oct 22.
    View in: PubMed
    Score: 0.062
  4. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther. 2024 Aug; 30(8):772.e1-772.e11.
    View in: PubMed
    Score: 0.060
  5. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 05 17; 14(1):82.
    View in: PubMed
    Score: 0.060
  6. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 May; 204(5):1944-1952.
    View in: PubMed
    Score: 0.059
  7. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.
    View in: PubMed
    Score: 0.059
  8. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672.
    View in: PubMed
    Score: 0.058
  9. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.
    View in: PubMed
    Score: 0.057
  10. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.
    View in: PubMed
    Score: 0.057
  11. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.
    View in: PubMed
    Score: 0.056
  12. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.
    View in: PubMed
    Score: 0.056
  13. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.
    View in: PubMed
    Score: 0.055
  14. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.
    View in: PubMed
    Score: 0.055
  15. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.
    View in: PubMed
    Score: 0.054
  16. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.
    View in: PubMed
    Score: 0.053
  17. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
    View in: PubMed
    Score: 0.052
  18. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.
    View in: PubMed
    Score: 0.052
  19. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8.
    View in: PubMed
    Score: 0.052
  20. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.
    View in: PubMed
    Score: 0.050
  21. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.044
  22. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.